Home -> Law Blog Directory -> Corporate & Securities Law Blogs -> Truth on the Market
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Corporate & Securities Law
: Truth on the MarketKobayashi & Wright on Antitrust Limits, Federalism and Patent Holdup
I’ve posted to SSRN my new article (co-authored by my colleague Bruce Kobayashi), Federalism, Substantive Preemption, and Limits on Antitrust: An Application to Patent Holdup. We presented an earlier version of our analysis at the George Mason/ Microsoft Conference on the Law and Economics of Innovation and benefited significantly from comments from the discussants and participants. We take an approach grounded in the economics of federalism and recent Supreme Court antitrust jurisprudence in arguing for substantive limits on antitrust enforcement of patent holdup in favor of reliance on patent law as well as state common law. Along the way we discuss recent cases and enforcement actions involving patent holdup, including the D.C. Circuit’s decision in Rambus, Broadcom, and N-Data. If you’re a reader interested in patent holdup and related issues, please give the paper a read. Comments welcome (here or email me).
Here is the abstract:
In Credit Suisse v. Billing, the Court held that the securities law implicitly precludes the application of the antitrust laws to the conduct alleged in that case. The Court considered several factors, including the availability and competence of other laws to regulate unwanted behavior, and the potential that application of the antitrust laws would result in unusually serious mistakes. This paper examines whether similar considerations suggest restraint when applying the antitrust laws to conduct that is normally regulated by state and other federal laws. In particular, we examine the use of the antitrust laws to regulate the problem of patent hold up of members of standard setting organizations. While some have suggested that this conduct illustrates a gap in the current enforcement of the antitrust laws, our analysis finds that such conduct would be better evaluated under the federal patent laws and state contract laws.
Full post as published by Truth on the Market on June 16, 2008 (boomark / email).
Zantac Patent
GlaxoSmithKline and Cypress Pharmaceutical settle patent infringement dispute.
Soliris Patent
Alexion Pharmaceuticals Inc. agrees to pay the Oklahoma Medical Research Foundation a $10 million patent infringement settlement.
DRAM Patent
ProMOS Technologies and Mosel Vitelic pay MOSAID Technologies an undisclosed patent infringement settlement.
Sony
to Pay $18.5 Million For Patent Infringment
Qualcomm Settles Patent Suit for $891 Million
Mississippi Antitrust
Costs Microsoft $100 Million

Federalism, Substantive Preemption, and Limits on Antitrust
Do Patent Holdup and Royalty Stacking Lead to Systematically Excessive Royalties
Patent Holdup and Oligopsonistic Collusion in Standard Setting Organizations
Patent and Antitrust: Differing Shades of Meaning
Orrick adds IP litigator William Wright as partner in L.A.
Profit Neutrality in Licensing: The Boundary between Antitrust Law and Patent Law









